Key facts
- This page summarizes Mark E. Bunnage's Form 3 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Feb 2026, 16:09.
Mark E. Bunnage - 01 Feb 2026 Form 3 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP, Chief Scientific Officer
- Issuer ticker
- VRTX
- Reported as of
- 01 Feb 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Feb 2026, 16:09:29 UTC
- Next SEC filing
- 12 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Bunnage filed Form 3 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 03 Feb 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002100735
Primary reporting owner
Bunnage Mark E.
- Relationship
- EVP, Chief Scientific Officer
- Address
- C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
- Signature
- /s/ Christiana Stevenson, Attorney-in-Fact
- Signature date
- 03 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,062
- Date
- 01 Feb 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24 - Power of Attorney